|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Fulcrum Therapeutics, Inc. (FULC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
63,029,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases. Co. has developed a proprietary product engine, FulcrumSeek, that it employs to systematically identify and validate cellular drug targets. Co.' products include: losmapimod, a small molecule that it is developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive and disabling disorder characterized by muscle degeneration and fat infiltration; and FTX-6058, an investigational oral fetal hemoglobin, inducer that is in development for sickle cell disease and select other hemoglobinopathies, including ss-thalassemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
43,360 |
43,360 |
43,360 |
4,472,361 |
Total Buy Value |
$492,028 |
$492,028 |
$492,028 |
$39,173,214 |
Total People Bought |
1 |
1 |
1 |
2 |
Total Buy Transactions |
1 |
1 |
1 |
7 |
Total Shares Sold |
5,120 |
5,120 |
5,120 |
150,153 |
Total Sell Value |
$59,050 |
$59,050 |
$59,050 |
$1,271,940 |
Total People Sold |
1 |
1 |
1 |
2 |
Total Sell Transactions |
2 |
2 |
2 |
8 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gould Robert J |
See Remarks |
|
2020-06-01 |
4 |
AS |
$20.00 |
$100 |
D/D |
(5) |
549,031 |
|
- |
|
Cadavid Diego |
SVP Clinical Development |
|
2020-05-29 |
4 |
AS |
$20.04 |
$4,007 |
D/D |
(200) |
66,785 |
|
- |
|
Cadavid Diego |
SVP Clinical Development |
|
2020-05-29 |
4 |
OE |
$4.83 |
$966 |
D/D |
200 |
66,985 |
|
- |
|
Gould Robert J |
See Remarks |
|
2020-05-29 |
4 |
AS |
$20.08 |
$27,911 |
D/D |
(1,390) |
549,036 |
|
- |
|
Cadavid Diego |
SVP Clinical Development |
|
2020-05-28 |
4 |
AS |
$20.00 |
$12,000 |
D/D |
(600) |
66,785 |
|
- |
|
Cadavid Diego |
SVP Clinical Development |
|
2020-05-28 |
4 |
OE |
$4.83 |
$2,898 |
D/D |
600 |
67,385 |
|
- |
|
Gould Robert J |
See Remarks |
|
2020-05-28 |
4 |
AS |
$20.01 |
$38,391 |
D/D |
(1,919) |
550,426 |
|
- |
|
Wallace Owen B. |
Chief Scientific Officer |
|
2020-05-28 |
4 |
AS |
$20.00 |
$44,640 |
D/D |
(2,232) |
127,088 |
|
- |
|
Wallace Owen B. |
Chief Scientific Officer |
|
2020-05-28 |
4 |
OE |
$7.84 |
$17,499 |
D/D |
2,232 |
129,320 |
|
- |
|
Wallace Owen B. |
Chief Scientific Officer |
|
2020-05-27 |
4 |
AS |
$20.00 |
$8,960 |
D/D |
(448) |
127,088 |
|
- |
|
Wallace Owen B. |
Chief Scientific Officer |
|
2020-05-27 |
4 |
OE |
$7.84 |
$3,512 |
D/D |
448 |
127,536 |
|
- |
|
Gould Robert J |
See Remarks |
|
2020-05-26 |
4 |
AS |
$20.00 |
$50,000 |
D/D |
(2,500) |
552,345 |
|
- |
|
Wallace Owen B. |
Chief Scientific Officer |
|
2020-05-26 |
4 |
AS |
$20.00 |
$8,240 |
D/D |
(412) |
127,088 |
|
- |
|
Wallace Owen B. |
Chief Scientific Officer |
|
2020-05-26 |
4 |
OE |
$7.84 |
$3,230 |
D/D |
412 |
127,500 |
|
- |
|
Cadavid Diego |
SVP Clinical Development |
|
2020-05-12 |
4 |
AS |
$18.00 |
$33,480 |
D/D |
(1,860) |
66,785 |
|
- |
|
Cadavid Diego |
SVP Clinical Development |
|
2020-05-12 |
4 |
OE |
$4.83 |
$8,984 |
D/D |
1,860 |
68,645 |
|
- |
|
Thomson Peter G. |
VP Finance & Accounting |
|
2020-05-11 |
4 |
AS |
$16.00 |
$120,000 |
D/D |
(7,500) |
21,071 |
|
- |
|
Cadavid Diego |
SVP Clinical Development |
|
2020-03-02 |
4 |
AS |
$17.26 |
$37,255 |
D/D |
(2,143) |
66,785 |
|
- |
|
Thomson Peter G. |
VP Finance & Accounting |
|
2020-02-24 |
4 |
AS |
$16.18 |
$84,153 |
D/D |
(5,000) |
28,571 |
|
- |
|
Wallace Owen B. |
Chief Scientific Officer |
|
2020-02-19 |
4 |
AS |
$20.00 |
$121,760 |
D/D |
(6,088) |
127,088 |
|
- |
|
Wallace Owen B. |
Chief Scientific Officer |
|
2020-02-19 |
4 |
OE |
$7.84 |
$47,730 |
D/D |
6,088 |
133,176 |
|
- |
|
Gould Robert J |
See Remarks |
|
2020-02-19 |
4 |
AS |
$20.00 |
$50,000 |
D/D |
(2,500) |
554,845 |
|
- |
|
Cadavid Diego |
SVP Clinical Development |
|
2020-02-03 |
4 |
AS |
$17.33 |
$37,142 |
D/D |
(2,143) |
68,928 |
|
- |
|
Thomson Peter G. |
VP Finance & Accounting |
|
2020-01-23 |
4 |
AS |
$17.17 |
$86,102 |
D/D |
(5,000) |
33,571 |
|
- |
|
Glaxosmithkline Plc |
|
|
2019-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
1,785,714 |
1,785,714 |
|
- |
|
122 Records found
|
|
Page 4 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|